The Future of Biosimilars - A Case of Untapped Potential?
The patents on a majority of the top-selling biologic drugs currently on the market will have expired by 2020, an amount which may be equivalent to $67 billion. Can we expect then a rush of biosimilar products to the market, drastically lowering spend on biological drugs? If current trends are anything to go by, the answer is maybe not.
If you prefer to receive a copy via email contact us at enquiryIQPC@iqpc.com with the subject line 'The Future of Biosimilars - A Case of Untapped Potential? - Article Request'
Please note: That all fields marked with an asterisk (*) are required.